ResearchPod Summary
This study aimed to compare the clinical and radiographic outcomes of two primary shoulder replacement procedures—anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (rTSA)—in patients diagnosed with osteoarthritis who had an intact rotator cuff and no history of prior shoulder surgery.
The researchers conducted a retrospective analysis of 740 patients (370 in each group) from an international, multi-institutional registry. Patients were matched for age, sex, and follow-up duration. All procedures utilized a single-platform shoulder system. The study evaluated patients using six standardized outcome scoring metrics, four active range of motion (ROM) measurements, and radiographic assessments at a minimum of 2 years post-surgery.
At a mean follow-up of 41 months, both groups demonstrated excellent pain relief and high patient satisfaction. While clinical outcomes and function were generally similar, aTSA patients showed greater external rotation. Notably, the aTSA group experienced a significantly higher rate of complications (4.9%) compared with the rTSA group (2.2%). Revision rates were similar between the two cohorts. The study suggests that rTSA is a viable, safe alternative to aTSA for patients with an intact rotator cuff, offering comparable functional results with a lower risk of adverse events.
Traditionally, aTSA has been the standard for patients with an intact rotator cuff, while rTSA was reserved for more complex cases like cuff tear arthropathy. This study provides evidence that rTSA can be used effectively in a broader range of patients, potentially reducing the complication burden associated with traditional anatomic replacements.
[[RP_SECTION:shoulder-arthroplasty-hierarchy|Shoulder Arthroplasty Hierarchy]]
Alex: [measured, professional, moderate pace] The traditional hierarchy of shoulder arthroplasty is effectively inverted. The anatomical total shoulder replacement — long considered the gold standard for patients with an intact rotator cuff — actually carries a higher burden of complications than the reverse construct.
Sam: [curious, leaning in] That's a significant claim. Is this from a clinical trial or a registry analysis? [[RP_SECTION:registry-study-methodology|Registry Study Methodology]]
Alex: [steady, matter-of-fact] It's the primary finding from a 2022 multicenter registry study in the Journal of the American Academy of Orthopaedic Surgeons, by Richard Friedman and colleagues. They used a propensity-matched cohort of 740 patients, split evenly between the two procedures. Both groups achieved solid pain relief and high satisfaction — but the anatomical group showed notably higher rates of adverse events, driven largely by glenoid loosening.
Sam: [analytical, probing] And how did they handle selection bias? Surgeons typically reach for the reverse construct in patients with worse bone stock or more severe deformity, which should make that group look worse, not better.
Alex: [deliberate] They used one-to-one nearest-neighbor matching on age, sex, and follow-up duration. Think of it like testing two engine types in the same chassis — by holding the driver and road conditions constant, you isolate the mechanical performance of the implant itself. It's a reasonable approach, though it has a ceiling, and we should come back to that.
Sam: [nodding] Fair enough. But if the anatomical design is biomechanically built for rotation, did patients actually notice a difference in daily function? [[RP_SECTION:functional-outcomes-comparison|Functional Outcomes Comparison]]
Alex: [precise] That's the crucial distinction. The anatomical group did show statistically greater external rotation — but the reverse group was functionally competitive across nearly every other metric. And when you apply the minimal clinically important difference threshold, external rotation is the only domain where the anatomical approach actually pulls ahead in a way that matters to the patient.
Sam: So the anatomical approach buys you one specific range-of-motion advantage, but at a worse safety profile. That's a real trade-off.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.
Alex: [measured] It is. And the authors argue it's enough to reframe how we think about the reverse construct. They're not saying it should replace the anatomical design categorically — they're saying the 'salvage procedure' label no longer holds. For patients with an intact cuff, the reverse is a viable primary option, provided the surgeon understands what they're trading away in external rotation.
Sam: [probing] What were the specific failure modes on the anatomical side? Was it purely loosening? [[RP_SECTION:failure-modes-and-limitations|Failure Modes and Limitations]]
Alex: [analytical] Primarily glenoid and humeral loosening, plus some rotator cuff tears — which makes mechanistic sense, because the anatomical design places the glenoid component under shear stress that the reverse geometry avoids by shifting the center of rotation medially and inferiorly. The reverse group had a more diverse complication profile — infections, component dissociation — but at lower overall frequency.
Sam: Did the implant platform or surgeon variation factor in?
Alex: [honest] They used a single-platform system across all sites, which standardizes the hardware. But surgeon-specific rehab protocols and site-level variation remain uncontrolled — the authors flag this as a residual confound. It's the kind of thing a registry design can identify but can't fully resolve.
Sam: [pushing back] And the follow-up window — 41 months on average. That's under four years. Is that long enough to capture the true failure rate of a glenoid component?
Alex: [reflective] It's the primary limitation, and it's a meaningful one. Glenoid loosening is a long-term failure mode. At under four years, you're catching early mechanical failures, but late-stage degradation — the kind that shows up at seven or ten years — is almost certainly undercounted. The complication gap between the two constructs could narrow, widen, or invert at longer follow-up. We don't know yet.
Sam: [analytical] And even with propensity matching, there's a residual selection problem. Surgeons who chose the anatomical implant may have done so precisely because the patient had better bone stock — a variable that wasn't captured in the matching algorithm.
Alex: [acknowledging] The authors admit that. Glenoid morphology and bone density likely influenced the initial implant choice, and those variables weren't fully measured. So some of the reverse group's favorable safety signal could reflect unmeasured patient-level advantages rather than implant-level superiority. That's the honest read of what the data can and can't support.
Sam: So the load-bearing finding is that the reverse construct is competitive on function and safer on complications — but that conclusion is constrained by a short observation window and the limits of registry matching. [[RP_SECTION:future-clinical-directions|Future Clinical Directions]]
Alex: [quiet confidence] That's exactly right. The study's contribution is shifting the prior: the reverse construct is no longer a fallback. But the next methodological step is a predictive model that integrates preoperative imaging and bone density — moving beyond the current binary choice toward implant selection that's tailored to the individual patient's anatomy and long-term risk profile.
Sam: [thoughtful] The field is shifting from asking which procedure is better, to asking which procedure is better for this patient.
Alex: [settling the point] And this study gives surgeons the evidence to have that conversation seriously. The reverse construct has earned a place in primary planning — not as the default, but as a genuine option rather than a last resort. Thanks for listening to ResearchPod.